It is currently believed that the targeted drug resistance mechanism of melanoma contains the following aspects: reactivation of the MAPK pathway [17], activation of substitutive pathways (PI3K-mTOR pathway) [18–21], alteration of the tumor microenvironment [22–24], autophagy and ER stress of tumor cells [25–27], miRNA-mediated resistance [28, 29], and therapy-mediated selection of resistant tumor cell subpopulations [30]. This evidence concerns the gene MTOR and neoplasm.